CVAC News and Press, CureVac N.V. From 05/25/22

CureVac is broadening its foundation in oncology, leveraging recent progress with its second-generation mRNA backbone The partnership combines CureVac's mRNA technology with myNEO's platform for the discovery and selection of tumor antigens predicted to elicit strong immune responses ...

Progressing broad vaccine development program in collaboration with GSK, with second-generation candidates in Phase 1 clinical trials for COVID-19 and influenza CureVac eligible to a €10 million milestone payment from GSK for the initiation of the influenza clinical trial ...

Image source: The Motley Fool. CureVac (NASDAQ: CVAC) Q1 2022 Earnings Call Apr 28, 2022 , 9:00 a.m. ET Operator Continue reading For further details see: CureVac (CVAC) Q1 2022 Earnings Call Transcript

CureVac NV (CVAC) Q4 2021 Earnings Conference Call April 28, 2022, 09:00 ET Company Participants Sarah Fakih - VP Corporate Communications & IR Franz-Werner Haas - CEO Klaus Edvardsen - Chief Development Officer Pierre Kemula - CFO Conference Call Participants Douglas Buchanan - JMP Secur...

CureVac BV press release (NASDAQ:CVAC): Q4 Pre-tax loss of €4.5M. Revenue of €41.2M (+586.7% Y/Y). Cash and cash equivalents decreased to €811.5 million as of December 31, 2021, from €1,322.6 billion as of December 31, 2020. Shares -1.19% PM. ...

- Executing on broad vaccine development program, with new clinical studies in COVID-19 and influenza together with GSK to validate advanced second-generation mRNA backbone - Initiated Phase 1 dose-escalation study in COVID-19 with CV2CoV, validating mRNA backbone for further variant ada...

ABG,ABMD,AEP,AIT,ALNY,AOS,ARES,ASPN,ASPS,ASX,OTCPK:ATGFF,BAX,BC,BCS,BFH,BTU,CARR,CAT,OTCPK:CDUAF,CFR,CG,CHD,CMCSA,CNX,CRS,CVAC,CWT,CX,CYBE,DPZ,DTE,EME,ERJ,FAF,FBP,FCN,FCNCA,FLWS,OTCQB:FMCC,FTV,GLOP,GLYC,GOL,GTX,GVA,GWW,HSY,HUN,HZO,ICLR,IP,IPG,IRM,JKS,KBR,KDP,KEX,KIM,LAZ,LECO,LH,LIN,LKQ,LLNW,L...

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 22, 2022 / CureVac N.V. (NASDAQ:CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the...

CureVac (NASDAQ:CVAC) shares are trading higher in the pre-market Thursday after the German biotech announced promising pre-clinical data for a second-generation bivalent COVID-19 vaccine candidate it jointly develops with GlaxoSmithKline (NYSE:GSK). In the study, the animals were immunized o...

- Vaccine candidate combining Beta- and Delta-specific mRNAs shows strong protection and immune responses during preclinical challenge study - Demonstrated neutralizing capacity against the Omicron variant in vaccinated animals - Technology adaptation for bivalent approach for COVI...